Pharmaceutical Business Consultants Limited
$59.4K 43 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Kairos Surgical Inc
Kairos Surgical Inc reported $59,443.95 across General Payments, Research, and Ownership to 537 physicians and teaching hospitals across 537 transactions.
- $59.4K Below-median payer
- All-tracks total
- 537 Above-median volume
- Transactions
- 537 Above-median reach
- Recipients
- −$18.0K
- General Payments vs PY2023
Kairos Surgical Inc reported $59,443.95 across all CMS Open Payments tracks (General + Research + Ownership) to 537 physicians and teaching hospitals in Program Year 2024 - ranking #1315 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $59,443.95, averaging $110.70 per recipient.
Kairos Surgical Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
16/100
Total payments
F
11/100
Transaction volume
F
14/100
Physician reach
F
14/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer kairos-surgical-inc Kairos Surgical Inc
$59.4K · #1315/1,925 · 0.0% industry · PY2024
- TOT $59.4K
- RANK #1315
- SHARE 0.0%
- TXN 537
- RCP 537
- CAT 2
- GEN $59.4K
- ΔGEN −$18.0K
- TOP1 3.4%
- PY 2024
Volume peers
Nearest volume peer: Pharmaceutical Business Consultants Limited ($59.4K)
Kairos Surgical Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Kairos Surgical Inc's CMS-reported General Payments decreased by $18.0K (−23.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: KAIROS SURGICAL INCPY2023: KAIROS SURGICAL INCPY2024: Kairos Surgical Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $77,452.51
- PY2024
- $59,443.95
What the Data Shows for Kairos Surgical Inc
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Kairos Surgical Inc that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
96 transactions worth $31.7K make "Travel and Lodging" the top general-payment category in the 2-category breakdown below, 53.2% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Travel and Lodging" leads Kairos Surgical Inc's 2-category general-payment breakdown at $31.7K, 53.2% of the reported total.
How Kairos Surgical Inc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $31.7K | 96 | 53.2% |
| Food and Beverage | $27.8K | 441 | 46.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $8,330.75 (14.0%) of $59,443.95 in this company's General Payments records across 298 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Kairos Surgical Inc
The five named recipients with the highest reported General Payments from this company
- 1
Daniel Shubert
$2,015.36 across 3 reported transactions
- 2
Christopher Chihlas
$1,789.80 across 4 reported transactions
- 3
Sarav Shah
$1,784.64 across 10 reported transactions
- 4
Ian Madom
$1,501.04 across 3 reported transactions
- 5
Erica Bayly
$1,239.91 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Kairos Surgical Inc ranks #1315 of 1,925 by total payments (bottom 32% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,660 of 1,838 by HHI (bottom 10% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Immunitybio, Inc. : $67.8K total payments, HHI 122
- Geistlich Pharma, North America, Inc. : $255.0K total payments, HHI 122
- Esperion Therapeutics, Inc. : $1.3M total payments, HHI 121
- Microtransponder, Inc. : $46.1K total payments, HHI 120
- Harmony Biosciences LLC : $1.3M total payments, HHI 120
- Jazz Pharmaceuticals Inc. : $9.9M total payments, HHI 119
- Kairos Surgical Inc (this company) : $59.4K total payments, HHI 119
- Antares Pharma, Inc. : $489.5K total payments, HHI 119
- Corcept Therapeutics : $3.9M total payments, HHI 117
- Orthofix Medical, Inc. : $9.6M total payments, HHI 116
- Exact Sciences Corporation : $3.5M total payments, HHI 115
- BIOTRONIK NRO, Inc. : $814.5K total payments, HHI 114
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Kairos Surgical Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Kairos Surgical Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Kairos Surgical Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Natus Medical Incorporated
$59.5K 13 recipients
Compare payment profiles
IZI Medical Products, LLC
$59.6K 15 recipients
Compare payment profiles
Trevena, Inc.
$59.3K 52 recipients
Compare payment profiles
Vasc-Alert LLC
$59.1K 4 recipients
Compare payment profiles
Ascend Laboratories LLC
$60.0K 12 recipients
Compare payment profiles
Put this to use
Kairos Surgical Inc ranks #1315 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Kairos Surgical Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.